[go: up one dir, main page]

PE20211417A1 - Analogos novedosos de glp-1 - Google Patents

Analogos novedosos de glp-1

Info

Publication number
PE20211417A1
PE20211417A1 PE2020001535A PE2020001535A PE20211417A1 PE 20211417 A1 PE20211417 A1 PE 20211417A1 PE 2020001535 A PE2020001535 A PE 2020001535A PE 2020001535 A PE2020001535 A PE 2020001535A PE 20211417 A1 PE20211417 A1 PE 20211417A1
Authority
PE
Peru
Prior art keywords
analogs
glp
refers
action
duration
Prior art date
Application number
PE2020001535A
Other languages
English (en)
Inventor
Rajamannar Thennati
Nishith Chaturvedi
Vinod Sampatrao Burade
Pradeep Dinesh Shahi
Muthukumaran Natarajan
Ravishankara Madavati Nagaraja
Rishit Mansukhlal Zalawadia
Kunal Pandya
Brijeshkumar Patel
Dhiren Rameshchandra Joshi
Krunal Harishbhai Soni
Abhishek Tiwari
Vipulkumar Shankarbhai Patel
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of PE20211417A1 publication Critical patent/PE20211417A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transmission And Conversion Of Sensor Element Output (AREA)

Abstract

Esta referido a analogos novedosos del peptido similar al glucagon-1 (GLP-1) (7-37) que tienen una secuencia de aminoacidos con Leu o Ile en el C-terminal. Los nuevos analogos son potentes agonistas de GLP-1 con efecto adverso reducido y duracion de la accion mejorada. Tambien se refiere a derivados acilados de los nuevos analogos que tienen una potencia y duracion de la accion mejoradas adicionalmente y son adecuados para la administracion oral. Los analogos de la solicitud pueden ser utiles en el tratamiento de la diabetes y la obesidad.
PE2020001535A 2018-04-05 2019-04-05 Analogos novedosos de glp-1 PE20211417A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201821013109 2018-04-05
IN201821040474 2018-10-26
IN201821040468 2018-10-26
PCT/IB2019/052835 WO2019193576A1 (en) 2018-04-05 2019-04-05 Novel glp-1 analogues

Publications (1)

Publication Number Publication Date
PE20211417A1 true PE20211417A1 (es) 2021-08-02

Family

ID=66589592

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001535A PE20211417A1 (es) 2018-04-05 2019-04-05 Analogos novedosos de glp-1

Country Status (33)

Country Link
US (7) US11447535B2 (es)
EP (3) EP4364751A3 (es)
JP (2) JP7250814B2 (es)
KR (2) KR102801994B1 (es)
CN (3) CN112236444B (es)
AU (3) AU2019247936C1 (es)
BR (1) BR112020020419A2 (es)
CA (1) CA3095988A1 (es)
CL (1) CL2020002574A1 (es)
CO (1) CO2020012425A2 (es)
DK (2) DK3774862T3 (es)
EC (1) ECSP20070185A (es)
ES (2) ES2925678T3 (es)
FI (1) FI4122954T3 (es)
HR (2) HRP20221054T1 (es)
HU (2) HUE060135T2 (es)
IL (1) IL277483B1 (es)
JO (1) JOP20200251A1 (es)
LT (2) LT3774862T (es)
MX (2) MX2020010505A (es)
MY (1) MY202560A (es)
NZ (1) NZ768446A (es)
PE (1) PE20211417A1 (es)
PH (1) PH12020551591A1 (es)
PL (2) PL3774862T3 (es)
PT (2) PT4122954T (es)
RS (2) RS65639B1 (es)
SG (1) SG11202009467YA (es)
SI (2) SI4122954T1 (es)
SM (2) SMT202200352T1 (es)
UA (1) UA128210C2 (es)
WO (1) WO2019193576A1 (es)
ZA (1) ZA202306729B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2925678T3 (es) * 2018-04-05 2022-10-19 Sun Pharmaceutical Ind Ltd Nuevos análogos de GLP-1
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
US12533315B2 (en) 2019-03-01 2026-01-27 President And Fellows Of Harvard College Compositions comprising at least one ionic liquid, a polypeptide, and at least one non-ionic surfactant for protein delivery
TW202216746A (zh) * 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
AU2021361263A1 (en) * 2020-10-17 2023-02-16 Sun Pharmaceutical Industries Limited GLP-1/GIP dual agonists
CN114685646B (zh) * 2020-12-31 2023-04-07 厦门赛诺邦格生物科技股份有限公司 一种多肽侧链类似物的制备方法及其应用
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
KR102873595B1 (ko) 2021-09-15 2025-10-22 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 장애의 치료를 위한 조성물 및 방법
JP2024544920A (ja) * 2021-11-10 2024-12-05 アイ２オー セラピューティクス，インク． イオン液体組成物
CN115785249B (zh) * 2022-10-13 2023-07-21 江苏师范大学 一类glp-1类似物及其应用
CN121285571A (zh) 2023-06-09 2026-01-06 太阳医药工业有限公司 Glp-1/gip双重、glp-1/gcg双重和glp-1/gip/gcg三重受体激动剂
WO2024261580A1 (en) 2023-06-20 2024-12-26 Sun Pharmaceutical Industries Limited Glp-1 analog for use in the treatment of metabolic disorders
CN117756914B (zh) * 2023-12-15 2024-09-03 瀚晖制药有限公司 依柯胰岛素的制备方法
WO2025163615A1 (en) 2024-01-31 2025-08-07 Sun Pharmaceutical Industries Ltd. High level production of glp1 analogues

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
KR100556067B1 (ko) 1996-08-30 2006-03-07 노보 노르디스크 에이/에스 지엘피 - 1 유도체
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
EP1056775B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
WO1999043705A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
DE69942306D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As Abkömmlinge von glp-1 analogen
EP1062240B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S N-terminally modified glp-1 derivatives
FR2777283B1 (fr) 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CZ295890B6 (cs) 1998-12-07 2005-11-16 Societe De Conseils De Recherches Et D'application Analogy GLP-1, mající kyselinu aminoizomáselnou pozici 8 a D-arginin na pozici 36, jejich použití a farmaceutické prostředky je obsahující
JP4716641B2 (ja) 2000-06-16 2011-07-06 イーライ リリー アンド カンパニー グルカゴン様ペプチド−１類似体
BR0116024A (pt) 2000-12-07 2005-12-13 Lilly Co Eli Proteìna de fusão heteróloga e uso da mesma
JP4282485B2 (ja) 2002-01-08 2009-06-24 イーライ リリー アンド カンパニー 伸長グルカゴン様ペプチド−１アナログ
KR20050049525A (ko) 2002-10-11 2005-05-25 가부시키가이샤산와카가쿠켄큐쇼 Ｇｌｐ-1 유도체 및 그의 경점막 흡수형 제제
EP1626981A4 (en) 2003-03-04 2006-11-22 Biorexis Pharmaceutical Corp PROTEINS PROTECTED AGAINST DIPEPTIDYLPEPTIDASE
ATE549028T1 (de) 2003-05-15 2012-03-15 Tufts College Stabile analoga von glp-1
WO2005027978A2 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
EP1711523B1 (en) 2003-12-16 2012-10-10 Ipsen Pharma Analogues of glp-1
EP1799710A2 (en) 2004-10-07 2007-06-27 Novo Nordisk A/S Protracted glp-1 compounds
TWI372629B (en) * 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
BRPI0608516A2 (pt) * 2005-03-18 2010-11-16 Novo Nordisk As análogo de glp-1, método para aumentar o tempo de ação em um paciente de um análogo de glp-1, composição farmacêutica, e, uso de um composto
EP1883419A4 (en) 2005-05-06 2010-08-04 Bayer Pharmaceuticals Corp GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL USES
AU2006287562B2 (en) 2005-09-08 2012-05-10 Trustees Of Tufts College Stabilized GLP-1 analogs
ES2397289T3 (es) 2005-09-22 2013-03-06 Biocompatibles Uk Ltd. Polipéptidos de fusión de GLP-1 (péptido 1 de tipo glucagón) con resistencia a peptidasa incrementada
ES2532116T3 (es) 2007-09-05 2015-03-24 Novo Nordisk A/S Péptidos derivados con A-B-C-D y sus usos terapéuticos
EP2214691B1 (en) 2007-10-30 2015-09-30 Indiana University Research and Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
MX2012006634A (es) 2009-12-16 2012-06-21 Novo Nordisk As Derivados de peptidos tipo glucagon 1 de doble acilato.
AU2011247824B2 (en) 2010-04-27 2014-02-13 Betta Pharmaceuticals Co., Ltd Glucagon-like peptide-1 analogue and use thereof
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
WO2012062803A1 (en) 2010-11-09 2012-05-18 Novo Nordisk A/S Double-acylated glp-1 derivatives
RU2602601C2 (ru) 2011-04-12 2016-11-20 Ново Нордиск А/С Дважды ацилированные производные glp-1
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
WO2013037690A1 (en) 2011-09-06 2013-03-21 Novo Nordisk A/S Glp-1 derivatives
EP2578599A1 (en) 2011-10-07 2013-04-10 LanthioPep B.V. Cyclic analogs of GLP-1 and GLP-1 related peptides
EP2846823B1 (en) 2012-05-08 2019-12-04 Novo Nordisk A/S Double-acylated glp-1 derivatives
ES2629735T3 (es) 2012-05-08 2017-08-14 Novo Nordisk A/S Derivados de GLP-1 doblemente acilados
MX2014015423A (es) 2012-06-14 2015-04-09 Sanofi Sa Analogos de peptido de exedina-4.
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI617574B (zh) 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
SG11201503526UA (en) 2012-12-21 2015-06-29 Sanofi Sa Dual glp1/gip or trigonal glp1/gip/glucagon agonists
CN105377306B (zh) 2013-06-20 2020-03-17 诺和诺德股份有限公司 Glp-1衍生物和其用途
WO2014209886A1 (en) 2013-06-23 2014-12-31 Wisconsin Alumni Research Foundation Alpha/beta-polypeptide analogs of glucagon-like peptid-1
AR096789A1 (es) 2013-07-04 2016-02-03 Novo Nordisk As Derivados de péptidos similares a glp-1 y usos de los mismos
US10266577B2 (en) 2013-08-15 2019-04-23 Novo Nordisk A/S GLP-1 derivatives, and uses thereof
ES2688708T3 (es) * 2013-10-17 2018-11-06 Zealand Pharma A/S Análogos de glucagón acilados
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086731A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
WO2015086686A2 (en) 2013-12-13 2015-06-18 Medimmune Limited Protease resistant peptides
JP6730278B2 (ja) 2014-11-27 2020-07-29 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体及びその使用
US10392428B2 (en) 2014-12-17 2019-08-27 Novo Nordisk A/S GLP-1 derivatives and uses thereof
TWI726889B (zh) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
US10111932B2 (en) 2015-08-26 2018-10-30 Syracuse University Coagonists of glucagon-like peptide 1 receptor and neuropeptide Y2 receptor
US10946074B2 (en) 2016-03-03 2021-03-16 Novo Nordisk A/S GLP-1 derivatives and uses thereof
WO2017211922A2 (en) 2016-06-09 2017-12-14 Medimmune Limited Protease-resistant mono-lipidated peptides
JP7076442B2 (ja) 2016-11-07 2022-05-27 ノヴォ ノルディスク アー／エス Ｐｅｇ化合物のｄｃｈｂｓ活性エステル及びその使用
TW201833131A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
WO2018178796A1 (en) * 2017-03-27 2018-10-04 Sun Pharmaceutical Industries Limited Method for making kex1 protease sensitive polypeptides using yeast strain
CN119060201A (zh) 2018-03-09 2024-12-03 费森尤斯卡比有限公司 利拉鲁肽、索马鲁肽和glp-1的化学酶促合成
ES2925678T3 (es) * 2018-04-05 2022-10-19 Sun Pharmaceutical Ind Ltd Nuevos análogos de GLP-1

Also Published As

Publication number Publication date
DK4122954T3 (da) 2024-06-10
MX2024007688A (es) 2024-07-09
ES2925678T3 (es) 2022-10-19
US11485766B2 (en) 2022-11-01
IL277483A (en) 2020-11-30
AU2019247936C1 (en) 2023-06-15
EP4122954A1 (en) 2023-01-25
EP3774862A1 (en) 2021-02-17
FI4122954T3 (fi) 2024-06-18
US20220402991A1 (en) 2022-12-22
HRP20221054T1 (hr) 2022-11-11
AU2025242190A1 (en) 2025-10-23
US20200362007A1 (en) 2020-11-19
US20210206823A1 (en) 2021-07-08
CN117964735A (zh) 2024-05-03
AU2023203430B2 (en) 2025-07-03
HUE067499T2 (hu) 2024-10-28
PT3774862T (pt) 2022-09-05
US11447535B2 (en) 2022-09-20
ECSP20070185A (es) 2021-01-29
PH12020551591A1 (en) 2021-08-16
LT3774862T (lt) 2022-09-12
SMT202400241T1 (it) 2024-07-09
KR20200141469A (ko) 2020-12-18
CA3095988A1 (en) 2019-10-10
SG11202009467YA (en) 2020-10-29
AU2019247936A1 (en) 2020-10-15
SI3774862T1 (sl) 2022-10-28
JP2023078367A (ja) 2023-06-06
AU2019247936B2 (en) 2023-03-02
MX2020010505A (es) 2021-01-15
HRP20240749T1 (hr) 2024-09-13
DK3774862T3 (da) 2022-09-05
US20240376175A1 (en) 2024-11-14
MY202560A (en) 2024-05-08
US11873328B2 (en) 2024-01-16
LT4122954T (lt) 2024-06-25
UA128210C2 (uk) 2024-05-08
EP4364751A3 (en) 2024-06-26
EP4122954B1 (en) 2024-04-03
US20220402992A1 (en) 2022-12-22
HUE060135T2 (hu) 2023-02-28
IL277483B1 (en) 2026-01-01
AU2023203430A1 (en) 2023-06-29
US12421289B2 (en) 2025-09-23
EP3774862B1 (en) 2022-06-08
PT4122954T (pt) 2024-06-05
US20240199718A1 (en) 2024-06-20
US20190309040A1 (en) 2019-10-10
JOP20200251A1 (ar) 2020-10-04
PL3774862T3 (pl) 2022-10-03
KR20250065720A (ko) 2025-05-13
NZ768446A (en) 2025-10-31
US11866477B2 (en) 2024-01-09
ZA202306729B (en) 2024-03-27
RS65639B1 (sr) 2024-07-31
CN120554480A (zh) 2025-08-29
CN112236444A (zh) 2021-01-15
WO2019193576A1 (en) 2019-10-10
CO2020012425A2 (es) 2020-12-21
ES2980707T3 (es) 2024-10-02
EP4364751A2 (en) 2024-05-08
PL4122954T3 (pl) 2024-08-12
US11242373B2 (en) 2022-02-08
JP2021520346A (ja) 2021-08-19
BR112020020419A2 (pt) 2021-01-19
SI4122954T1 (sl) 2024-07-31
JP7250814B2 (ja) 2023-04-03
CN112236444B (zh) 2025-09-19
KR102801994B1 (ko) 2025-04-30
CL2020002574A1 (es) 2021-06-04
SMT202200352T1 (it) 2022-09-14
RS63523B1 (sr) 2022-09-30

Similar Documents

Publication Publication Date Title
PE20211417A1 (es) Analogos novedosos de glp-1
PE20170954A1 (es) Compuestos co-agonistas de gip y glp-1
CO2019005924A2 (es) Agonistas duales acilados de glp-1/glp-2
MX2021000793A (es) Compuestos coagonistas de gip/glp1.
PE20220590A1 (es) Agonistas del receptor del peptido-1 similar al glucagon
AR067555A1 (es) Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal
PE20240215A1 (es) Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo
PE20180158A1 (es) Coagonistas de los receptores de glucagon y de glp-1
MX2023000303A (es) Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral.
PE20221518A1 (es) Analogos de incretina y sus usos
MX2020011007A (es) Derivado de péptido-1 (glp-1) similar al glucagón acilado.
AR069136A1 (es) Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1 (peptido somilar al glucagon tipo 1) y usos de los mismos
CO6541617A2 (es) Método para tratar la insuficiencia cardíaca con péptidos tipo estrescopina
AR128464A1 (es) Péptidos agonistas duales glp-1 y glucagón con estabilidad biológica mejorada
PE20251259A1 (es) Agonista dual de glp-1/gip, metodo de preparacion y uso del mismo
AR094358A1 (es) Derivados de péptidos insulinotrópicos cuya carga n-terminal está modificada
AR131483A1 (es) Agonista triple novedoso del receptor de glp-1 / gip / glucagón y una composición farmacéutica para prevenir o tratar la obesidad que lo comprende
AR119324A1 (es) Composiciones farmacéuticas para péptidos co-agonistas de glucagón y glp-1
TH2001005828A (th) Glp-1 อนาล็อกชนิดใหม่
EA202092017A1 (ru) Новые аналоги glp-1
AR107282A1 (es) Agonista triple que tiene actividad para un receptor de glucagón, un receptor del péptido 1 similar al glucagón (glp-1) y un receptor de péptido insulinotrópico dependiente de glucosa (gip)
NZ771617A (en) Glucagon derivatives
NZ733649B2 (en) Glucagon derivatives
NZ771617B2 (en) Glucagon derivatives